Remove 2021 Remove Safety Remove Side effects
article thumbnail

Novel anti-epileptic drug demonstrates efficacy

European Pharmaceutical Review

A new approach to potassium-channel openers for epilepsy Critically, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, stated study lead author and neurologist Dr Jacqueline French. It ran between January 2019 and September 2021.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

Such developments, including a 2021 approval of AstraZeneca’s Saphnelo (anifrolumab) , prompted The Lancet Rheumatology to posit that 2022 could be a “banner year” for the condition. The CAR-T therapies for conditions like lupus continue to look promising, but their safety is a concern, says Gilkeson. MSCs and CAR-Ts for lupus.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First FDA pregnancy-approved Pertussis vaccine to protect newborns

European Pharmaceutical Review

percent of whooping cough cases in 2021 were those six months or younger. Side effect data related to those given the non-US variation during pregnancy was consistent with data for individuals who were given the non-US formulation post labour. The US Centres for Disease Control and Prevention (CDC) estimate that 4.2

FDA 105
article thumbnail

Oral drug reduces treatment-resistant migraine frequency

European Pharmaceutical Review

“These results are exciting… this treatment led to fewer days with migraine for people who had already tried up to four other types of drugs to prevent migraine and either had no improvement or had side effects that outweighed any benefits,” commented study author Dr Patricia Pozo-Rosich, PhD at Vall d’Hebron University Hospital in Barcelona, Spain.

article thumbnail

European approval for third adapted COVID-19 vaccine

European Pharmaceutical Review

The safety profile of the adapted vaccine is expected to be like that of the originally authorised Nuvaxovid, EMA said. The most common side effects with Nuvaxovid XBB.1.5 Nuvaxovid was first authorised in the European Union in December 2021. Based on these data, the Committee concluded that Nuvaxovid XBB.1.5

article thumbnail

FDA clears Incyte’s Opzelura as first vitiligo therapy

pharmaphorum

Steroids can be used to slow down progression of the condition, but can cause significant side effects if used too much and do nothing to restore the usual skin colour. Opzelura (ruxolitinib) is now the first alternative to steroid drugs for vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5

FDA 98
article thumbnail

FDA drug dosage optimisation guidelines signal clinical trial reform

Pharmaceutical Technology

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The focus on identifying the ideal drug dosage is not new.

FDA 115